STOCK TITAN

Vistagen Therapeutics Inc - VTGN STOCK NEWS

Welcome to our dedicated page for Vistagen Therapeutics news (Ticker: VTGN), a resource for investors and traders seeking the latest updates and insights on Vistagen Therapeutics stock.

Vistagen Therapeutics Inc (VTGN) is a clinical-stage biopharmaceutical company pioneering neuroscience-focused treatments through innovative stem cell technology. This page provides investors and industry professionals with essential updates on the company’s progress, including press releases, clinical trial milestones, and strategic developments.

Access real-time information on VTGN’s advancements in predictive toxicology, drug metabolism screening, and neuropsychiatric therapies. Our curated news collection ensures you stay informed about regulatory submissions, partnership announcements, and financial disclosures without needing to track multiple sources.

Key updates include progress in stem cell-derived bioassay systems, FDA communications regarding therapeutic candidates, and insights into the company’s unique approach to in vitro testing. All content is verified for accuracy and relevance to support informed decision-making.

Bookmark this page for streamlined access to VTGN’s latest developments. Check back regularly for authoritative reporting on advancements in neuroscience and biotechnology that could shape the future of drug discovery.

Rhea-AI Summary
Vistagen (NASDAQ: VTGN) will host a conference call and webcast on February 13, 2024, to report results for its fiscal year 2024 third quarter and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.58%
Tags
conferences earnings
-
Rhea-AI Summary
Vistagen (Nasdaq: VTGN) announced positive preclinical and Phase 1 clinical data for AV-101, a potential treatment for neuropathic pain, with a favorable safety profile. The European Patent Office issued a Notice of Intention to Grant a patent related to the use of AV-101 for the treatment of neuropathic pain, adding to Vistagen's global patent portfolio on therapeutic uses and manufacturing techniques for AV-101.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.38%
Tags
none
-
Rhea-AI Summary
Vistagen (Nasdaq: VTGN) reports positive Phase 3 results for fasedienol in the treatment of social anxiety disorder (SAD), with preparations underway for potential NDA-enabling Phase 3 studies in 2024. The company secured $137.7 million in gross proceeds, including $100 million from an underwritten public offering of equity securities, strengthening its financial position for future developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.07%
Tags
Rhea-AI Summary
Vistagen (Nasdaq: VTGN) announces participation in Stifel 2023 Healthcare Conference to present corporate overview and host one-on-one meetings, offering webcast accessibility through the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.49%
Tags
conferences
-
Rhea-AI Summary
Vistagen (Nasdaq: VTGN) announces positive top-line results from fasedienol (PH94B) Phase 3 PALISADE-2 trial for social anxiety disorder and Phase 2A study for vasomotor symptoms, with plans to initiate a Phase 3 clinical trial for SAD in early 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
conferences clinical trial
-
Rhea-AI Summary
Vistagen (NASDAQ: VTGN) will host a conference call and webcast on November 9, 2023, to provide a corporate update and report results for its fiscal year 2024 second quarter. The event will start at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). Participants can access the webcast via the provided link and a telephone playback will be available after the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
conferences earnings
Rhea-AI Summary
Vistagen to present and host meetings at Jefferies Biotech CNS/Neuro Summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.04%
Tags
conferences
-
Rhea-AI Summary
Vistagen Therapeutics announces pricing of $100 million underwritten offering of its common stock and warrants, led by BVF Partners LP and other institutional investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.85%
Tags
none
-
Rhea-AI Summary
Vistagen's PH80 nasal spray showed statistically and clinically significant improvement in a Phase 2A study for premenstrual dysphoric disorder (PMDD). The spray demonstrated improvement in negative mood and physical and behavioral symptoms. PH80 also showed significant improvement in symptoms as early as Day 4 and continuing to Day 6. Headache was the most common adverse event. The results suggest a potential treatment option for PMDD and reinforce the potential of PH80 in women's healthcare.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
Rhea-AI Summary
Vistagen and Fuji Pharma enter into a time-limited agreement for exclusive negotiation regarding a potential license for Vistagen's PH80 in Japan. Fuji will pay $1.5 million for exclusive rights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.9%
Tags
none
Vistagen Therapeutics Inc

Nasdaq:VTGN

VTGN Rankings

VTGN Stock Data

60.90M
28.79M
0.26%
52.64%
2.25%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO